Healthcare Global Enterprises Ltd Stock Analysis

BSE: 539787 | NSE: HCG | Miscellaneous | Small Cap

BSE Share Price 02-Dec-2022 18:01
304.70 2.30 (0.76%)

DeciZen - Make an Informed Decision on HealthcareGlobal

Overall Rating

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Semi Strong

HealthcareGlobal Price Chart

P/E Ratio (CD) :
0.00
Market Cap :
4,237.8 Cr.
52-wk low :
221.1
52-wk high :
320
Bole Toh?

1. Is Healthcare Global Enterprises Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Healthcare Global Enterprises Ltd is a below average quality company.

2. Is Healthcare Global Enterprises Ltd undervalued or overvalued?

The key valuation ratios of Healthcare Global Enterprises Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Healthcare Global Enterprises Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Healthcare Global Enterprises Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of HealthcareGlobal:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Healthcare Global Enterprises Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 2.7%-2.6%4.6%4.1%4.4%4.3%2.1%-1%-9.5%1.8%-
Value Creation Index -0.8-1.2-0.7-0.7-0.7-0.7-0.9-1.1-1.7-0.9-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 3454505195847008299761,0921,0091,3951,548
YoY Gr. Rt. %-30.3%15.4%12.5%19.9%18.4%17.8%11.9%-7.6%38.2%-
Adj EPS -0.9-5.50.50.32.41.5-2.9-12.2-15.4-3.3-1.9
YoY Gr. Rt. %-NANA-42.6%680.7%-40.1%-298.6%NANANA-
BVPS (₹) 43.538.239.35050.355.453.642.251.662.163.4
Adj Net Profit -6.1-37.63.82.720.712.6-25.3-108-193-45.8-26
Cash Flow from Ops. 28.649.659.773.291.397.898.5130121220-
Debt/CF from Ops. 10.85.45.84.44.64.76.75.53.91.9-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 16.8%14.8%12.6%38.2%
Adj EPS NA-206.4%NANA
BVPS 4.14.35.120.5
Share Price - 0.6% 44% 22%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % -2.4-13.51.40.84.82.7-5.1-25.1-35.9-5.9-3
Op. Profit Mgn % 158.214.714.61513.612.615.512.116.917.6
Net Profit Mgn % -1.6-7.91.51.13.11.3-2.1-10.5-21.9-4.4-1.7
Debt to Equity 1.111.30.8111.41.90.70.50.4
Working Cap Days 125112109117126136144151179126113
Cash Conv. Cycle -12-27-35-50-49-38-27-120-104

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 12.64%

Debt to equity has declined versus last 3 years average to 0.47

Sales growth is good in last 4 quarters at 24.72%

Return on Equity is Poor

Latest Financials - Healthcare Global Enterprises Ltd.

Standalone Consolidated
TTM EPS (₹) -2.5 -1.9
TTM Sales (₹ Cr.) 930 1,548
BVPS (₹.) 80.8 63.4
Reserves (₹ Cr.) 985 742
P/BV 3.77 4.82
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 221.05 / 320.00
All Time Low / High (₹) 62.95 / 352.00
Market Cap (₹ Cr.) 4,238
Equity (₹ Cr.) 139.1
Face Value (₹) 10
Industry PE 26.1

Management X-Ray of HealthcareGlobal :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.003.363.473.473.003.003.003.09
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of HealthcareGlobal

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Healthcare Global Enterprises Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of HealthcareGlobal on 02-Dec-2022 18:01 is : 304.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Dec-2022 18:01 the market cap of HealthcareGlobal stood at ₹ 4,237.8.
The latest PE ratio of HealthcareGlobal as of 02-Dec-2022 18:01 is 0.00.
The latest PB ratio of HealthcareGlobal as of 02-Dec-2022 18:01 is 3.77
The 52-week high of HealthcareGlobal is ₹ 320.0 and the 52-week low is ₹ 221.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of HealthcareGlobal is ₹ 930.4 ( Cr.) .

About Healthcare Global Enterprises Ltd

Healthcare Global Enterprises was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. The company was converted into a public limited company pursuant to a special resolution passed by its Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of the company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006.

The company is a provider of speciality healthcare services in India focused on cancer and fertility. Under the “HCG” brand, it operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB . Under the “Milann” brand, it operates its fertility centres.

The company’s HCG network operates on a “hub and spoke” model, wherein its HCG centre of excellence in Bengaluru serves as a “hub” to its other cancer centres. Its centre of excellence provides its other centres access to centralised quality control and assurance services; establishes treatment protocols that are adhered to across its HCG network; provides centralised treatment planning and tele-radiology services to help with diagnosis and treatment; conducts weekly central tumour board meetings to review complex cases; and also gives its HCG network access to advanced technologies, such as WBRRS and specialised procedures such as liver transplants and stem cell therapies. This model allows HCG network of cancer centres to leverage the expertise and capabilities of its centre of excellence, which when combined with the diagnostic and treatment facilities at its cancer centres, allows it to deliver quality cancer care to patients across India in a seamless manner.

The company follows a multidisciplinary approach to cancer care across its HCG network, wherein specialist physicians from various disciplines collaborate to provide the best course of treatment for each patient. This allows it to share and develop best practices, build clinical expertise and adopt standardised protocols for diagnosis and treatment, thereby improving the quality of its cancer care services. As a result, the company is able to better serve its patients and ensure consistent clinical outcomes.

Given the large number of patient cases treated across its HCG network, the company is able to efficiently utilise its equipment, technologies and human resources, thereby deriving economies of scale. Furthermore, through the adoption of a centralised drug and consumables formulary, it is able to lower the overall cost of drugs and consumables. Its business model is scalable and when combined with efficient utilisation of resources, it enables it to operate within a competitive cost structure.

Business area of the company

The company is Bangalore based provider of speciality healthcare in India focused on cancer and fertility. It operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed. It also operates fertility centres under the ‘Milann’ brand.

Major events and milestones

  • 2005: Entered into the clinical laboratory business through acquisition of Triesta Sciences Inc. and Triesta Sciences (India) Private Limited.
  • 2006: India Development Fund made its first investment of Rs 500 million in the company,
  • 2006: BMORCL became its subsidiary.
  • 2007: HCG Medi-Surge became its subsidiary.
  • 2007: Evolvence made its first investment of Rs 225 million in the company,
  • 2008: NTICPL made its first investment of Rs 400 million in the company.
  • 2009: Amalgamation of Triesta Sciences (India) Private Limited and Triesta Sciences Inc. with the company.
  • 2010: IL&FS Trust Company Limited a/c MPEF, through its scheme India Build Out Fund I and MAT made its first investment of Rs 312 million in the company.
  • 2011: Amalgamation of BMORCL with the company.
  • 2011: PIOF became a Shareholder by purchasing shares from NTICPL.
  • 2013: V-Sciences made its first investment of Rs 600 million in the company.
  • 2013: Entered into the fertility business through acquisition of 50.10% stake in BACC Healthcare.
  • 2014: Demerger of multispecialty division from HCG Medi-Surge and vesting of the same with the company.
  • 2015: HCG Regency became its subsidiary.
  • 2015: Amalgamation of HCG Vijay with the company.

Awards and accreditations

  • 2010: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
  • 2011: The company and its Triesta Reference Laboratory received CAP accreditation valid up to August 25, 2015.
  • 2011: The company received the ‘Oncology Leader of the Year’ award from Frost and Sullivan.
  • 2012: HCG cancer centre at Bengaluru received NABH accreditation valid up to May 11, 2018.
  • 2013: The company received the ‘Best Place to Work in Indian Healthcare’ award from People Strong and HOSMAC.
  • 2013: HMS, Ahmedabad received NABH accreditation valid up to June 22, 2016.
  • 2013: Triesta Reference Laboratory received accreditation from the National Accreditation Board for Testing and Caliberation Laboratories for its facilities at HCG Tower, Bengaluru in the field of medical testing valid up to October 13, 2015.
  • 2013: The company was designated an ESMO Designated Centre of Integrated Oncology and Palliative Care.
  • 2013: The company received the ‘Most Innovative Single Specialty Healthcare Entity’ award from VC Circle.
  • 2014: The company received the ‘Golden Peacock Award for Innovation in Management’ from the Institute of Directors.
  • 2014: Its pathology laboratory at HMS received ISO 9001 certification valid up to August 30, 2017.
  • 2015: The company received recognition from the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India for its in-house research and development wing at HCG Tower, Bengaluru.

 

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now